Form 8-K - Current report:
SEC Accession No. 0001437749-25-005338
Filing Date
2025-02-27
Accepted
2025-02-27 07:31:53
Documents
17
Period of Report
2025-02-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K sava20250224_8k.htm   iXBRL 8-K 33614
2 EXHIBIT 10.1 ex_781585.htm EX-10.1 293009
3 EXHIBIT 99.1 ex_783266.htm EX-99.1 21078
8 casslogo.jpg GRAPHIC 16041
  Complete submission text file 0001437749-25-005338.txt   558948

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA sava-20250227.xsd EX-101.SCH 3409
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sava-20250227_def.xml EX-101.DEF 11807
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE sava-20250227_lab.xml EX-101.LAB 15858
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sava-20250227_pre.xml EX-101.PRE 12022
19 EXTRACTED XBRL INSTANCE DOCUMENT sava20250224_8k_htm.xml XML 2955
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41905 | Film No.: 25673030
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)